Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
Clinical trial NCT04857164 · RECRUITING
Trial details
- NCT number
- NCT04857164
- Sponsor
- Yuankai Shi
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-30
- Primary completion
- 2023-08-20
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.